These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Significance of aldose-reductase inhibition with traditional Chinese and Western drugs in the treatment of diabetic peripheral neuropathy]. Liang X; Guo S Zhongguo Zhong Xi Yi Jie He Za Zhi; 1999 Jul; 19(7):442-4. PubMed ID: 11783220 [No Abstract] [Full Text] [Related]
4. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. Schemmel KE; Padiyara RS; D'Souza JJ J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287 [TBL] [Abstract][Full Text] [Related]
5. [Prevention and treatment of diabetic neuropathy]. Uesaka Y Nihon Rinsho; 2002 Oct; 60 Suppl 10():256-9. PubMed ID: 12430238 [No Abstract] [Full Text] [Related]
6. Treatment of diabetic neuropathy with inhibitors of the aldose reductase enzyme. Green AJ; Jaspan JB J Diabet Complications; 1990; 4(4):138-44. PubMed ID: 2151223 [No Abstract] [Full Text] [Related]
7. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy. Yue DK; Brooks B Med J Aust; 1993 Jul; 159(2):76-8. PubMed ID: 8336605 [No Abstract] [Full Text] [Related]
8. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. El-Kabbani O; Wilson DK; Petrash M; Quiocho FA Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955 [TBL] [Abstract][Full Text] [Related]
9. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine. Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319 [TBL] [Abstract][Full Text] [Related]
10. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]. Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of ranirestat for the treatment of diabetic neuropathy. Giannoukakis N Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1051-9. PubMed ID: 24785785 [TBL] [Abstract][Full Text] [Related]
14. [Progress in diagnosis of and therapy for diabetic polyneuropathies]. Baba M Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1556-62. PubMed ID: 15384682 [No Abstract] [Full Text] [Related]
15. Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats. Shimoshige Y; Minoura K; Matsuoka N; Takakura S; Mutoh S; Kamijo M Brain Res; 2009 Jan; 1247():182-7. PubMed ID: 18992730 [TBL] [Abstract][Full Text] [Related]